ArticleThe Pan African medical journal2017
[Epidemiological profile of uropathogenic enterobacteria producing extended spectrum beta-lactamases].
Article in The Pan African medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Prevalence and molecular characterization of ESBL-producing Enterobacterales in clinical samples from the Boucle du Mouhoun region in Burkina Faso.BMC infectious diseases · 2026Article
- Aminoglycoside Resistance Among Clinical Bacterial Isolates in Sétif, Algeria: Epidemiology, Multidrug Resistance, and Virulence Features.Antibiotics (Basel, Switzerland) · 2026Article
- Tracking multidrug-resistant bacteria: a one-year retrospective study at Moulay Ismail Military Hospital, Meknes, Morocco.The Pan African medical journal · 2026Article
- Epidemiological Profile of Uropathogenic Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.Interdisciplinary perspectives on infectious diseases · 2026Article
- Molecular Characterization and Antibiotic Resistance of Broad-SpectrumInternational journal of microbiology · 2026Article
- Extended-spectrum beta-lactamases: definition, history, an update on their genetic environment and detection methods.Journal of medical microbiology · 2025Review
- Characterization of Extended-Spectrum Beta-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- Predictive factors of urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children: a prospective Tunisian study.La Tunisie medicale · 2023Observational
- Phenotypic characterization and epidemiology of extended-spectrumFrontiers in public health · 2023Article
- The Prevalence of Multidrug-ResistantHealthcare (Basel, Switzerland) · 2022Article
- Article
- Molecular characterization of multiresistant enterobacteria in two departments of the Peruvian jungleBiomedica : revista del Instituto Nacional de Salud · 2021Article
- Heterogeneity of Antibiotics Multidrug-Resistance Profile of Uropathogens in Romanian Population.Antibiotics (Basel, Switzerland) · 2021Article
- Antibiotic Resistance Pattern of Extended Spectrum Beta Lactamase ProducingFrontiers in cellular and infection microbiology · 2021Article
- Current Antibiotic Resistance Trends of Uropathogens in Central Europe: Survey from a Tertiary Hospital Urology Department 2011-2019.Antibiotics (Basel, Switzerland) · 2020Article
- Prevalence of extended-spectrum beta-lactamase-producing enterobacterial urinary infections and associated risk factors in small children of Garoua, Northern Cameroon.The Pan African medical journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections due to enterobacteria producing extended spectrum beta-lactamases (ESBL-E) constitute a infectious risk, a major therapeutic challenge and can even lead, in some cases, to a deadlock beacuse of their multi-resistance to antibiotics. This study aimed to determine the epidemiological profile of uropathogenic ESBL-E and to describe their current level of resistance to antibiotics for a better patient management according to local data. We conducted a retrospective study of all ESBL-E strains isolated from all cytobacteriogical testing of urine (CBEU) treated in the Microbiology Laboratory at the Military Hospital of Moulay Ismail, Meknes over a period of three years (from 1 January 2013 to 31 December 2015). Culture was performed according to conventional techniques and antibiogram was performed using Mueller-Hinten agar disk diffusion susceptibility test according to the recommendations from the Committee on Antimicrobial Susceptibility of the French Society for Microbiology (CA-SFM), year 2013/2014. This study allowed to report a significant overall prevalence of isolation of ESBL-E (12.2%), particularly among hospitalized patients (54.8%). The greater prevalence (72%) was registered in the Department of Urology. Among these, ESBL-E Escherichia coli constitutes the majority (61%) of the isolates, however Klebsiella pneumoniae is the major ESBL producer (25.8%) within the same species. The analysis of ESBL-E antibioresistance conducted during these three years revealed some co-resistances to ciprofloxacin (92.5%), sulfametoxazole-trimethoprim (88.4%), gentamycin (67.2%). Globally, our results are compliant with the data from the other Mediterranean countries, except for amikacin whose resistance was very low (6.1%) in our study. This study shows that the prevalence of ESBL-E in hospital is high and that its diffusion in community setting is a matter of concern. These ESBL-E are generally resistant to antibiotics, including molecules useful in urology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.